NATIXIS ADVISORS, L.P. - CRINETICS PHARMACEUTICALS IN ownership

CRINETICS PHARMACEUTICALS IN's ticker is CRNX and the CUSIP is 22663K107. A total of 177 filers reported holding CRINETICS PHARMACEUTICALS IN in Q3 2023. The put-call ratio across all filers is 0.81 and the average weighting 0.5%.

Quarter-by-quarter ownership
NATIXIS ADVISORS, L.P. ownership history of CRINETICS PHARMACEUTICALS IN
ValueSharesWeighting
Q3 2023$762
+107.6%
25,630
+25.7%
0.00%
+100.0%
Q2 2023$367
+12.9%
20,387
+0.8%
0.00%0.0%
Q1 2023$325
+51.2%
20,222
+71.9%
0.00%0.0%
Q4 2022$215
-99.9%
11,764
-0.7%
0.00%0.0%
Q3 2022$233,000
+5.0%
11,848
-0.2%
0.00%0.0%
Q2 2022$222,00011,8770.00%
Other shareholders
CRINETICS PHARMACEUTICALS IN shareholders Q3 2023
NameSharesValueWeighting ↓
Versant Venture Management, LLC 2,030,616$31,028,0006.04%
5AM Venture Management, LLC 1,362,286$20,816,0003.75%
Burrage Capital Management LLC 272,393$4,162,0003.37%
Altium Capital Management LP 361,930$5,530,0001.54%
Vivo Capital, LLC 2,214,138$33,832,0001.19%
Bain Capital Life Sciences Investors, LLC 1,071,428$16,371,0000.93%
Perceptive Advisors 3,659,381$51,606,0000.65%
New Leaf Venture Partners, L.L.C. 141,000$2,154,0000.50%
DRIEHAUS CAPITAL MANAGEMENT LLC 2,003,688$30,616,0000.45%
Opaleye Management Inc. 188,000$2,873,0000.42%
View complete list of CRINETICS PHARMACEUTICALS IN shareholders